Background and study aim: Hepatocellular carcinoma (HCC) is the 4^th most common cancer in Egypt and is the 2^nd leading ‎cause of cancer-related death in both men and women. The aim of this study is to determine the ‎frequency of HCC in cirrhotic patients admitted in Al-Ahrar Teaching hospital especially after ‎hepatitis C virus (HCV) treatment with new direct-acting antivirals (DAAs)‎‎‎‎‎‎.
Patients and Methods: This study included 107 patients with liver cirrhosis admitted to Al-Ahrar Teaching hospital. All ‎patients undergo complete blood count, liver functions, kidney functions, coagulation profiles, ‎serology for viral hepatitis, serum alpha-fetoprotein, abdominal ultrasound, and tri-phasic computed ‎tomography.‎
Results: HCC was diagnosed in about 9 % of cirrhotic patients in this study. The etiology of cirrhosis was ‎HCV (66.4 %), non-viral causes (23.3 %), and HBV (9.3 %). There was no statistically significant ‎difference between HCC and non-HCC patients as regard viral markers and HCV treatment. ‎According to Barcelona-Clinic Liver Cancer staging, 80 % of patients among HCC group was ‎stage D while 20 % of patients were Stage A - C‎.
Conclusion: HCC is prevalent in cirrhotic patient admitted in Al-Ahrar Teaching Hospital. HCV treatment with ‎DAAs does not raise the risk of HCC occurrence in cirrhotic HCV patients‎‎‎‎‎‎‎‎.